1. Home
  2. PB vs COGT Comparison

PB vs COGT Comparison

Compare PB & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prosperity Bancshares Inc.

PB

Prosperity Bancshares Inc.

HOLD

Current Price

$72.31

Market Cap

6.5B

Sector

Finance

ML Signal

HOLD

Logo Cogent Biosciences Inc.

COGT

Cogent Biosciences Inc.

HOLD

Current Price

$39.17

Market Cap

6.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PB
COGT
Founded
1983
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5B
6.5B
IPO Year
1998
2018

Fundamental Metrics

Financial Performance
Metric
PB
COGT
Price
$72.31
$39.17
Analyst Decision
Buy
Buy
Analyst Count
13
13
Target Price
$81.17
$30.17
AVG Volume (30 Days)
741.9K
2.4M
Earning Date
01-28-2026
02-24-2026
Dividend Yield
3.20%
N/A
EPS Growth
19.26
N/A
EPS
5.60
N/A
Revenue
$1,239,671,000.00
N/A
Revenue This Year
$8.85
N/A
Revenue Next Year
$20.65
N/A
P/E Ratio
$12.93
N/A
Revenue Growth
7.88
N/A
52 Week Low
$61.07
$3.72
52 Week High
$82.75
$43.73

Technical Indicators

Market Signals
Indicator
PB
COGT
Relative Strength Index (RSI) 57.39 60.74
Support Level $71.22 $33.84
Resistance Level $73.59 $36.88
Average True Range (ATR) 1.40 1.93
MACD 0.11 0.07
Stochastic Oscillator 75.41 75.53

Price Performance

Historical Comparison
PB
COGT

About PB Prosperity Bancshares Inc.

Prosperity Bancshares Inc provides retail and commercial banking services to individuals and small to midsize businesses. It provides a wide array of financial products and services to businesses and consumers throughout Texas and Oklahoma. The group provides Personal, Business, Mortgage, and Banking Services.

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Share on Social Networks: